FDA accepts Pfizer Priority Review sNDA for TALZENNA plus XTANDI in HRR gene‑altered metastatic castration‑sensitive prostate cancer, PDUFA late 2026
https://finviz.com/stock?t=PFE&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.